Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00574509 · ClinicalTrials.gov registry record · Phase 1
Hematopoietic Stem Cell Transplant for Recurrent Non-Hodgkin's Lymphoma
A Phase 1 study, sponsored by University of Nebraska.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT00574509 is a Phase 1 study that has completed, run by University of Nebraska. The registered enrollment target is 34 participants.
The verdict
NCT00574509, a Phase 1 study, has completed, sponsored by University of Nebraska.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety of 131I-anti-B1 Radioimmunotherapy when combined with high-dose BEAM or BEAC chemotherapy and hematopoietic stem cell transplantation. The study will also compare the difference in response rates and time to treatment failure between historical control patients receiving high-dose BEAM or BEAC chemotherapy with autologous hematopoietic stem cell transplant and patients receiving radioimmunotherapy and high-dose BEAM or BEAC chemotherapy with autologous hematopoietic stem cell transplant. Patients will receive escalating doses of radioimmunotherapy with anti-B1 radiolabeled with 131Iodine, high-dose carmustine, etoposide, cytarabine and Melphalan (BEAM) chemotherapy, and autologous hematopoietic stem cell transplant.
Interventions
- DRUG BEAM
- RADIATION 131Iodine-Anti-B1 Radioimmunotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 1996-03-04 |
| Est. Completion | 2014-12-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00574509
The ClinicalTrials.gov registry entry for NCT00574509 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BEAM is the first listed.
NCT00574509 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00574509 about?
NCT00574509 is a clinical study titled "Hematopoietic Stem Cell Transplant for Recurrent Non-Hodgkin's Lymphoma". The purpose of this study is to assess the safety of 131I-anti-B1 Radioimmunotherapy when combined with high-dose BEAM or BEAC chemotherapy and hematopoietic stem cell transplantation. The study will also compare the difference in response rates and time to treatment failure between historical contr...
What is the current status of trial NCT00574509?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 1996-03-04. Estimated completion is 2014-12-10.
What interventions are being tested in trial NCT00574509?
The interventions under investigation include: BEAM (DRUG), 131Iodine-Anti-B1 Radioimmunotherapy (RADIATION).
Who is sponsoring clinical trial NCT00574509?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.